[en] Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective.
Disciplines :
Neurosciences & behavior Neurology
Author, co-author :
Tfelt-Hansen, P.
Saxena, P. R.
Dahlof, C.
Pascual, J.
Lainez, M.
Henry, P.
Diener, H.
Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Ferrari, M. D.
Goadsby, P. J.
Language :
English
Title :
Ergotamine in the acute treatment of migraine: a review and European consensus.
Adams M, Aikman P, Allardyce K. General practitioner clinical trials: treatment of migraine. Practitioner 1971; 206: 551-4.
Adham N, Kao H-T, Schecter LE, Bard J, Olsen M, Urquhart D, et al. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 1993; 90: 408-12.
Andersen AR, Tfelt-Hansen P, Lassen NA. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke 1987; 18: 120-3.
Bulow PM, Ibraheem JJ, Paalzow G, Tfelt-Hansen P. Comparison of pharmacodynamic effects and plasma levels of oral and rectal ergotamine. Cephalalgia 1986; 6: 107-11.
Buzzi MG, Moskowitz MA. Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991; 11: 165-8.
Buzzi MG, Moskowitz MA, Peroutka SJ, Byun B. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma extravasation in rat dura mater. Br J Pharmacol 1991; 103: 1421-8.
Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996; 41: 187-90.
Cortelli P, Pierangeli G, Corsini R, Prologo G, Limido GL. Pain control in migraine attacks: results from a double-blind, randomized, within-patient, placebo-controlled trial comparing diclofenac-K and ergotamine-caffeine. Cephalalgia 1996; 196: 359.
Cortijo J, Marti-Cabrera M, Bernabeu E, Domenech T, Bou J, Fernández AG, et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol 1997; 122: 1455-63.
Crooks J, Stephen SA, Brass W. Clinical trial of inhaled ergotamine tartrate in migraine. Br Med J 1964; 1: 221-4.
Dahlof C. Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. [Review]. Cephalalgia 1993; 13: 166-71.
De Vries P, Villalon CM, Heiligers JP, Saxena PR. Characterization of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors. Br J Pharmacol. 1998; 123: 1561-70.
Dichgans J, Diener H-C, Gerber WD, Verspohl EJ, Kukiolka H, Kluck M. Analgetika-induzierter Dauerkopfschmerz. Dtsch Med Wochenschr 1984; 109: 369-73.
Diener H-C, Tfelt-Hansen P. Headache associated with chronic use of substances. In: Olesen J, Tfelt-Hansen P, Welch KM, editors. The headaches. New York: Raven Press; 1993. p. 721-7.
Dixon RM, Meire HB, Evans DH, Watt H, On N, Posner J, et al. Peripheral vascular effects and pharmacokinetics of the antimigraine compound, zolmitriptan, in combination with oral ergotamine in healthy volunteers. Cephalalgia 1997; 17: 639-46.
Eulenberg A. Subcutane Injectionen von ergotinin (Tanret): Ergotinum citricum solutum (Gehe). Dtsch Med Wochenschr 1883; 9: 637-9.
Ferrari MD. Migraine. [Review]. Lancet 1998; 351: 1043-51.
Francis H, Tyndall A, Webb J. Severe vascular spasm due to erythromycin-ergotamine interaction. Clin Rheumatol 1984; 3: 243-6.
Friedman AP, Brazil P, von Storch TJ. Ergotamine tolerance in patients with migraine. J Am Med Assoc 1955; 157: 881-4.
Friedman AP, Di Serio FJ, Hwang DS. Symptomatic relief of migraine - multicenter comparison of Cafergot P-B, Cafergot, and placebo. Clin Ther 1989; 11: 170-82.
Galer BS, Lipton RB, Solomon S, Newman LC, Spierings EL. Myocardial ischemia related to ergot alkaloids: a case report and literature review. [Review]. Headache 1991; 31: 446-50.
Glusa E, Roos A. Endothelial 5-HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine. Br J Pharmacol 1996; 119: 330-4.
Gnecchi-Ruscone T, Lorenzoni R, Anderson D, Legg N, Tousoulis D, Winter PD, et al. Effects of ergotamine on myocardial blood flow in migraineurs without evidence of atherosclerotic coronary artery disease. Am J Cardiol. 1998; 81: 1165-8.
Goadsby PJ. Serotonin 5-HT1B/1D receptor agonists in migraine: comparative pharmacology and its therapeutic implications. CNS Drugs 1998; 10: 271-86.
Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33: 48-56.
Graves CR. Agents that cause contraction or relaxation of the uterus. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th edn. New York: McGraw-Hill; 1996. p. 939-49.
Hakkarainen H, Gustafsson B, Stockman O. A comparative trial of ergotamine tartrate, acetyl salicylic acid and a dextropropoxyphene compound in acute migraine attacks. Headache 1978; 18: 35-9.
Hakkarainen H, Vapaatalo H, Gothoni G, Parantainen J. Tolfenamic acid is as effective as ergotamine during migraine attacks. Lancet 1979; 2: 326-8.
Hakkarainen H, Quiding H, Stockman O. Mild analgesics as an alternative to ergotamine in migraine. A comparative trial with acetylsalicylic acid, ergotamine tartrate, and a dextropropoxyphene compound. J Clin Pharmacol 1980; 20: 590-5.
Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th edn. New York: McGraw-Hill; 1996. p. 199-248.
Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction. Arch Intern Med 1996; 156: 456-8.
Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiological study. Brain 1996; 119:249-56.
Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. [Review]. J Recept Res 1988; 8: 59-81.
Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Meylcharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). [Review]. Pharmacol Rev 1994; 46: 157-203.
Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol 1983; 16: 695-9.
International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. 1st edn. Cephalalgia 1991; 11: 1-12.
Johnston BM, Saxena PR. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol 1978; 63: 541-9.
Kangasniemi P, Kaaja R. Ketoprofen and ergotamine in acute migraine. J Intern Med 1992; 231: 551-4.
Kaube H, May A, Pfaffenrath V. Sumatriptan [letter]. Br Med J 1994; 308: 1573-4.
Kinnunen E, Erkinjuntti T, Farkkila M, Palomaki H, Porras J, Teirmaa H, et al. Placebo-controlled double-blind trial of pirprofen and an ergotamine tartrate compound in migraine attacks. Cephalalgia 1988; 8: 175-9.
Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG, Solbach MP, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51: 773-81.
Le Jeunne C, Pascual-Gomez J, Pradalier A, Titus i Albareda F, Joffroy A, Liano H, et al. Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. Eur Neurol 1999; 41: 37-43.
Lewis PJ, Barrington SF, Marsden PK, Maisey MN, Lewis LD. A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using (NH3)-N-13 positron emission tomography. Neurology 1997; 48: 1542-50.
Leysen JE, Gommeren W. In vitro receptor binding profile of drugs used in migraine. In: Amery WK, Van Nueten JM, Wauquier A, editors. The pharmacological basis of migraine therapy. London: Pitman; 1984. p. 255-66.
Leysen JE, Gommeren W, Heylen L, Luyten WH, Van de Weyer I, Vanhoenacker P, et al. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1Dα, human 5-hydroxytryptamine1Dβ, and calf 5-hydroxytryptamine1D receptors investigated with [3H]-5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol 1996; 50: 1567-80.
Liaudet L, Buclin T, Jaccard C, Eckert P. Drug points: severe ergotism associated with interaction between ritonavir and ergotamine. Br Med J 1999; 318: 771.
Limmroth V, Kazarawa S, Fritsche G, Diener HC. Headache after frequent use of serotonin agonists zolmitriptan and naratriptan [letter]. Lancet 1999; 353: 378.
Lipton RB, Stewart WF, Edmeads J, Sawyer J. Clinical utility of a new instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) score [abstract]. Headache 1998; 38: 390-1.
MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25-30.
Maier HW. L'ergotamine, inhibiteur du sympathique etudie en clinque, comme moyen d'exploration et comme agent therapeutique. Rev Neurol 1926; 33: 1104-8.
Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982; 22: 66-8.
Moir JC. Ergot: from 'St. Anthony's Fire' to isolation of its active principle, ergometrine (ergonovine). Am J Obstet Gynecol 1974; 47: 291-6.
Müller-Schweinitzer E. Ergot alkaloids in migraine: is the effect via 5-HT receptors? In: Olesen J, Saxena PR, editors. 5-Hydroxytryptamine mechanisms in primary headaches. New York: Raven Press; 1992. p. 297-304.
Müller-Schweinitzer E, Weidmann H. Basic pharmacological properties. In: Berde B, Schild HO, editors. Ergot alkaloids and related compounds. Handbook of experimental pharmacology, Vol. 49. Berlin: Springer-Verlag; 1978. p. 87-232.
Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991; 31: 314-22.
Østergaard JR, Mikkelsen E, Voldby B. Effects of 5-hydroxy-tryptamine and ergotamine on human superficial temporal artery. Cephalalgia 1981; 1: 223-8.
Ostfeld AM. A study of migraine pharmacotherapy. Am J Med Sci 1961; 241: 192-8.
Peroutka SJ. Drugs effective in the therapy of migraine. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th edn. New York: McGraw-Hill; 1996. p. 487-502.
Peters GA, Horton BT. Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proceedings of the Staff Meetings of the Mayo Clinic 1951; 26: 153-61.
Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25mg, 50mg, and 100mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184-90.
Pradalier A, Rancurel G, Dordain G, Verdure L, Rascol A, Dry J. Acute migraine attack therapy: comparison of naproxen sodium and an ergotamine tartrate compound. Cephalalgia 1985; 5: 107-13.
Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Neurology 1995; 45: 585-7.
Reches A, Eletriptan Steering Committee. Comparison of the efficacy, safety and tolerability of oral eletriptan and Cafergot[nabla] for the acute treatment of migraine [abstract]. Cephalalgia 1999; 19: 355.
Ryan RE. Double-blind clinical evaluation of the efficacy and safety of ergostine-caffeine, ergotamine-caffeine and placebo in migraine headache. Headache 1970; 9: 212-22.
Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol 1983; 30: 331-4.
Sargent JD, Baumel B, Peters K, Diamond S, Saper JR, Eisner LS, et al. Aborting a migraine attack: naproxen sodium V ergotamine plus caffeine. Headache 1988; 28: 263-6.
Saxena PR, Cairo-Rawlins WI. Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat. Eur J Pharmacol 1979; 58: 305-12.
Saxena PR, Ferrari MD. Pharmacology of antimigraine 5-HT1D receptor agonists. Expert Opin Invest Drugs 1996; 5: 581-93.
Stoll A. Zur Kenntnis der Mutterkornalkaloide. Verh Naturf Ges Basel 1918; 101: 190-1.
Swedish Medicines Agency. Sumatriptan versus cafergot suppositories. [Swedish]. 1978. [cited 1999 Aug 27]. Available from: URL: http://www.mpa.se/sve/mono/imig.shtml
Tfelt-Hansen P, Johnson ES. Ergotamine. In: Olesen J, Tfelt-Hansen P, Welch KM, editors. The headaches. New York: Raven Press; 1993. p. 313-22.
Thorns H. John Stearns 1808 Account of the pulvis parturiens, a remedy of quickening childbirth. Am J Obstet Gynecol 1931; 2: 418-23.
Treves TA, Streiffler M, Korczyn AD. Naproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache 1992; 32: 280-2.
Villalón CM, De Vries P, Rabelo G, Centurión D, Sánchez-López A, Saxena PR. Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/ ID receptors and α2-adrenoceptors. Br J Pharmacol 1999; 126: 585-94.
Visser WH, Burggraaf J, Muller LM, Schoemaker RC, Fowler PA, Cohen AF, et al. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 1996a; 60: 452-60.
Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996b; 16: 264-9.
Visser WH, de Vriend RH, Jaspers NM, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996c; 47: 46-51.
von Storch TJ. Complications following the use of ergotamine tartrate. J Am Med Assoc 1938; 111: 293-300.
Waters WE. Controlled clinical trial of ergotamine tartrate. Br Med J 1970; 2: 325-7.
Weiller C, May A, Limmroth V, Jüptner M, Kaube H, Schayck RV, et al. Brain stem activation in spontaneous human migraine attacks. Nature Med 1995; 1: 658-60.
Wolfson WQ, Graham JR. Development of tolerance to ergot alkaloids in a patient with unusually severe migraine. N Engl J Med 1949; 241: 296-8.
Yuill GM, Swinburn WR, Liversedge LA. A double-blind crossover trial of isometheptene mucate compound and ergotamine in migraine. Br J Clin Pract 1972; 26: 76-9.
